The US Food and Drug Administration raised concerns about Lupin Limited’s overall corporate quality system in an 11 June warning letter concerning the company’s Novel Laboratories Inc. facility in Somerset, NJ.
The agency drew a connection between poor manufacturing practices observed at the plant during an eight-week inspection that concluded 5 November
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?